Exdia TRF-LFIA同步定量GFAP与NT-proBNP鉴别缺血性与出血性卒中
本研究开发并验证了一种高灵敏时间分辨荧光侧向流免疫分析(TRF-LFIA),可同时定量检测血清胶质纤维酸性蛋白(GFAP)和N末端B型利钠肽前体(NT-proBNP)。该方法检测限分别为NT-proBNP 98 pg/mL和GFAP 68 pg/mL,交叉反应极小,并用200份临床人血清样本评估了平台相关性。联合GFAP与NT-proBNP形成的算法在区分缺血性卒中(IS)与出血性卒中(HS)中表现最佳,有望作为实验室或POCT的补充诊断方法。
要点
- Exdia TRF-LFIA可同时定量血清GFAP和NT-proBNP,检测限分别为68 pg/mL和98 pg/mL。
- 联合GFAP与NT-proBNP的算法是区分IS与HS最有效的生物标志物组合。
- 该平台用200份临床血清样本评估,相关性高,有望用于实验室或POCT。
核心结论
- Exdia TRF-LFIA可作为实验室或POCT的补充体外诊断方法,显著缩短IS与HS的诊断时间。
- 联合GFAP与NT-proBNP的算法是区分IS与HS最有效的生物标志物组合。
研究设计与样本
- 开发并验证新型TRF-LFIA,采用铕纳米颗粒(EuNPs)标记特异性单克隆抗体,在硝酸纤维素膜上设置NT-proBNP和GFAP两条检测线和一条质控线。
- 作为概念验证,纳入在特定时间窗(6 h)内入院的疑似卒中患者,使用少量血清临床标本。
- 用200份临床人血清样本评估该平台的相关性。
主要发现
- 检测限为NT-proBNP 98 pg/mL、GFAP 68 pg/mL,交叉反应极小。
- 该检测卡具有宽线性动态检测范围、快速检测、高灵敏度和特异性。
- 联合GFAP与NT-proBNP的结果形成了临床评估IS与HS的算法。
关键数值与推荐
- 检测限:NT-proBNP 98 pg/mL,GFAP 68 pg/mL。
- 临床评估使用200份人血清样本,平台相关性高。
- 疑似卒中患者入院时间窗为6 h。
临床怎么用
- 可利用Exdia TRF-LFIA同时定量血清GFAP和NT-proBNP,辅助区分缺血性与出血性卒中。
- 按所提算法联合解读GFAP与NT-proBNP结果,以缩短诊断时间并减少治疗延迟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The goal of this study is to create a highly sensitive time-resolved fluorescence lateral flow immunoassay (TRF-LFIA) capable of concurrently measuring glial fibrillary acidic protein (GFAP) and the N-terminal fragment of B-type natriuretic peptide precursor (NT-proBNP). This assay is designed as a diagnostic tool and aims to provide an algorithm for stroke management, specifically for distinguishing between Ischemic stroke (IS) and Hemorrhagic stroke (HS). However, LFIA to quantify simultaneous serum NT-proBNP and GFAP are not yet available. We have developed and validated a novel TRF-LFIA for the simultaneous quantitative detection of NT-proBNP and GFAP. The sensitivity and reproducibility of the immunoassay were significantly improved by employing specific monoclonal antibodies linked to europium nanoparticles (EuNPs) that specifically target NT-proBNP and GFAP. The detection area on the nitrocellulose membrane featured sandwich-style complexes containing two test lines for NT-proBNP and GFAP, and one Control line. The fluorescence intensity of these test lines and control line was measured using an in-house developed Exdia TRF-Plus analyzer. As proof-of-concept, we enrolled patients suspected of having a stroke who were admitted within a specific time frame (6 h). A small amount of clinical specimen (serum) was used. To optimize the LFIA, an EuNPs conjugated antibodies were investigated to improve the detection sensitivity and decrease the background signal as well shorten the detection time. The Exdia TRF-LFIA cartridge offers a wide linear dynamic detection range, rapid detection, high sensitivity, and specificity. The limit of detection was determined to be 98 pg/mL for NT-proBNP and 68 pg/mL for GFAP, with minimal cross-reactivity. There were 200 clinical human serum samples that were used to evaluate this platform with high correlation. By combining the results of NT-proBNP and GFAP, we formulated an algorithm for the clinical assessment of Ischemic Stroke (IS) and Hemorrhagic Stroke (HS). According to our proposed algorithm, the combination of GFAP and NT-proBNP emerged as the most effective biomarker combination for distinguishing between IS and HS. Exdia TRF-LFIA shows great potential as a supplemental method for in vitro diagnostics in the laboratory or in other point-of-care testing (POCT) applications. Its development substantially decreases the diagnosis time for IS and HS. The proposed algorithm not only minimizes treatment delays but also lowers medical costs for patients.
引用
- Lee M, Rafiq Sayyed D, Kim H, et al. A comprehensive Exdia TRF-LFIA for simultaneous quantification of GFAP and NT-proBNP in distinguishing ischemic and hemorrhagic stroke. Clin Chim Acta. 2024. PMID: 38471630. doi:10.1016/j.cca.2024.117872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。